KIRREL3-AS2: A Potential Drug Target and Biomarker (G100874251)

Target Name: KIRREL3-AS2

NCBI ID: G100874251

Other Name(s): KIRREL3 antisense RNA 2

KIRREL3-AS2: A Potential Drug Target and Biomarker

KIRREL3-AS2, a small non-coding RNA molecule, has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and biochemical properties make it an attractive target for drug development.

The KIRREL3-AS2 molecule is composed of 21 amino acid residues and has a molecular weight of 23.9 kDa. It is expressed in various tissues and cells in the body and is involved in various cellular processes, including cell growth, apoptosis, and inflammation.

KIRREL3-AS2 has been shown to play a critical role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a drug target and biomarker is due to its unique structure and biochemical properties, as well as its involvement in multiple cellular processes.

In cancer, KIRREL3-AS2 has been shown to be involved in cell growth, apoptosis, and angiogenesis. KIRREL3-AS2 has also been shown to be involved in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Its involvement in these diseases makes it an attractive potential drug target for the development of new treatments.

In addition to its potential as a drug target, KIRREL3-AS2 has also been shown to be a potential biomarker for several diseases. Its expression has been shown to be elevated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes KIRREL3-AS2 an attractive potential biomarker for the diagnosis and monitoring of these diseases.

The unique structure and biochemical properties of KIRREL3-AS2 make it an attractive target for drug development. Its small size and simple biochemical structure make it easy to synthesize and purify for use in experiments. Its involved role in multiple cellular processes also makes it a good candidate for drug targeting.

In conclusion, KIRREL3-AS2 is a promising drug target and biomarker with unique properties. Its involvement in multiple cellular processes and its potential as a drug target make it an attractive candidate for the development of new treatments for cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand its role and potential as a drug target and biomarker.

Protein Name: KIRREL3 Antisense RNA 2

More Common Targets